Get to know our clinical trials

Mayor respuesta a la Terapia de Resincronización Cardiaca (TRC) con Estimulación Multisitio

THE PURPOSE OF THIS STUDY IS TO DEMONSTRATE THAT ACTIVATION OF MULTIPOINT PACING (MPP) INCREASES THE RESPONSE RATE TO CARDIAC RESYNCHRONIZATION THERAPY IN PATIENTS WHO HAD NOT RESPONDED TO THIS THERAPY (NONRESPONDERS) AFTER 6 MONTHS OF FOLLOW-UP. THIS IS A SUMMARY OF THE CLINICAL TRIAL. ONCE YOU CONTACT US, WE WILL PROVIDE YOU WITH ALL THE INFORMATION YOU NEED.

Imagen Dr. Ignacio García Bolao, departamento de Cardiología
Dr. Ignacio García Bolao Curriculum
Director Cardiology Department
Navarre headquarters
Diseases
Terapia de resincronización cardíaca
Insuficiencia cardíaca
Status
In recruitment
headquarters
Pamplona

Technical Summary

  • INCREASED RESPONSE TO CARDIAC RESYNCHRONIZATION THERAPY (CRT) WITH MULTISITE PACING
  • Code EudraCT: -
  • Protocol number: CR-13-006-ID-HF
  • Promoter: St. Jude Medical España, S.A.
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Who can participate?

Patients must meet current Class I or IIa indications for CRT implantation according to ESC or ACCF/AHA/HRS guidelines (including single-chamber or dual-chamber ICD upgrades).